PHASE 0 & I STUDY EXPERIENCE INCLUDE:

• First-in-Human (FIM)Single Ascending Dose (SAD)
• Multiple Ascending Dose (MAD)
• Adaptive/Accelerated Protocols
• PK, PD, BD
• Food Effect
• Drug/Drug Interaction
• Age & Gender
• Special Populations with specific diseases(CHF, CRF, Malignancies etc.)
• Bioavailability/Bioequivalence (For Biosimilar or Generic Version)

PHASE I/II STUDIES:  NHCR will help the sponsor to combine Phase I and Phase II for:

• Efficacy (response to new treatment)
• Toxicity (safety, dosage levels)